The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Open accessAbstract
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationErdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationTransection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationMazzaferro, V., Regalia, E., Doci, R., Andreola, S. A., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,173
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,774
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Cited by
Sorted by citations
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Self-citationAASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
Self-citationEASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Self-citationSingal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 1,029
“Nevertheless, specific treatment decisions for individual patients are best made by mutidisciplinary teams of providers (for example, transplant hepatologists, surgeons, interventional radiologists and medical oncologists), nurses and patient navigators 91,167,168 .”
BackgroundMethodSelf-citationManagement of Hepatocellular Carcinoma
Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2022.7989 · Cited by 799
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 747
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01796-8 · Cited by 545
Ganesan, P., & Kulik, L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.004 · Cited by 489
Single test-based diagnosis of multiple cancer types using Exosome-SERS-AI for early stage cancers
Shin, H., Choi, B. H., Shim, O., Kim, J., Park, Y., Cho, S. K., Kim, H. K., & Choi, Y. (2023) · Nature Communications · doi:10.1038/s41467-023-37403-1 · Cited by 421
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA), & National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 364
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 416
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V. G., Mehta, N., Parikh, N. D., Abou‐Alfa, G. K., Singal, A. G., & Yang, J. D. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 359
Self-citationNeoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Zhu, H., Li, H.-L., Huang, M., Yang, W.-Z., Yin, G., Zhong, B., Sun, J., Jin, Z., Chen, J.-J., Ge, N., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01235-0 · Cited by 300
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Chan, S. L., Dawson, L. A., Kelley, R. K., Llovet, J. M., Meyer, T., Ricke, J., Rimassa, L., Sapisochín, G., Vilgrain, V., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.006 · Cited by 338
Self-citationBiomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 313
“The 2022 BCLC staging strategy recommended the ALBI score and AFP concentration for hepatic function assessment regardless of tumor burden [26].”
MethodPredictors of early and late hepatocellular carcinoma recurrence
Nevola, R., Ruocco, R., Criscuolo, L., Villani, A., Alfano, M., Beccia, D., Imbriani, S., Claar, E., Cozzolino, D., Sasso, F. C., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i8.1243 · Cited by 300
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
“Transarterial chemoembolization (TACE) has been globally adopted as the standard of care for patients with intermediate-stage (multinodular disease limited to the liver, and preserved liver function 17 ) HCC leading to a median OS >2.5 years 3,15,18–21 .”
BackgroundInfluentialBCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
Reig, M., Sanduzzi‐Zamparelli, M., Forner, A., Rimola, J., Ferrer, J., Burrel, M., García‐Criado, Á., Díaz, A., Llarch, N., Iserte, G., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.020 · Cited by 253
Self-citationHepatitis B Virus-Associated Hepatocellular Carcinoma
Rizzo, G. E. M., Cabibbo, G., & Craxı̀, A. (2022) · Viruses · doi:10.3390/v14050986 · Cited by 235
Vitale, A., Cabibbo, G., Iavarone, M. A., Viganò, L., Pinato, D. J., Ponziani, F. R., Lai, Q., Gardini, A. C., Celsa, C., Galati, G., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00186-9 · Cited by 209
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Huang, D. Q., Singal, A. G., Kanwal, F., Lampertico, P., Buti, M., Sirlin, C. B., Nguyen, M. H., & Loomba, R. S. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00818-8 · Cited by 201
“This lack of sensitivity for early disease is a major problem given that curative options are limited for advanced-stage HCC 11,17,28,53,54 .”
BackgroundSelf-citationXie, D., Shi, J., Zhou, J., Fan, J., & Gao, Q. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0402 · Cited by 177
“The China liver cancer staging (CNLC) system(Figure 1) incorporating tumor characteristics, liver function and performance status, similar to the Barcelona Clinic of Liver Cancer(BCLC) system[21], was established in 2017 and has been adopted ever since.”
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
Tümen, D., Heumann, P., Gülow, K., Demirci, C. N., Cosma, L.-S., Müller, M., & Kandulski, A. (2022) · Biomedicines · doi:10.3390/biomedicines10123202 · Cited by 192
Eslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 200
“When HCC is diagnosed at an early stage, there are existing acceptable and curative therapies, for example, surgical resection, local ablation, or liver transplantation [291].”
Kim, E., Sher, A., Abboud, G., Schwartz, M., Facciuto, M. E., Tabrizian, P., Knešaurek, K., Fischman, A. M., Patel, R. S., Nowakowski, S. F., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00091-7 · Cited by 171
Ducreux, M. P., Abou‐Alfa, G. K., Bekaii‐Saab, T., Berlin, J. D., Cervantes, A. M. R., de Baère, T., Eng, C., Galle, P. R., Gill, S., Gruenberger, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101567 · Cited by 167
“The results from one phase III trial showed that compared with TACE, hepatic arterial infusion of chemotherapy with oxaliplatin plus intravenous 5-fluorouracil (5-FU) and folinic acid significantly improved the overall survival with a significantly lower incidence of grade 3-4 adverse events for large and unresectable…”
BackgroundMethodInfluentialSelf-citationXie, D., Zhu, K., Ren, Z., Zhou, J., Fan, J., & Gao, Q. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-469 · Cited by 174
Breakthroughs in Hepatocellular Carcinoma Therapies
Singal, A. G., Kudo, M., & Bruix, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.039 · Cited by 167
Self-citationJin, Z., Chen, J.-J., Zhu, X., Duan, X.-H., Xin, Y., Zhong, B., Chen, J., Tie, J., Zhu, K., Zhang, L., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102622 · Cited by 168
Kudo, M., Aoki, T., Ueshima, K., Tsuchiya, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2023) · Liver Cancer · doi:10.1159/000529574 · Cited by 160
Safety and Efficacy of Robotic vs Open Liver Resection for Hepatocellular Carcinoma
Benedetto, F. D., Magistri, P., Sandro, S. D., Sposito, C., Oberkofler, C. E., Brandon, E., Samstein, B., Guidetti, C., Papageorgiou, A., Frassoni, S., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.5697 · Cited by 153
Self-citation2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
(2022) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0822 · Cited by 143
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
(2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.11.07 · Cited by 145
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Pinter, M., Scheiner, B., & Pinato, D. J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00147-4 · Cited by 139
Zhang, T., Geng, Z., Zuo, M., Li, J., Huang, J., Huang, Z.-L., Wu, P., & Gu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01663-6 · Cited by 138
Zeng, Q., Klein, C., Caruso, S., Maille, P., Allende, D. S., Mínguez, B., Iavarone, M. A., Ningarhari, M., Casadei-Gardini, A., Pedica, F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00468-0 · Cited by 135
Self-citationThe #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors
Mendiratta‐Lala, M., Wiggermann, P., Pech, M., Serres, X., White, S. B., Davis, C., Ahmed, O. S., Parikh, N. D., Planert, M., Thormann, M., et al. (2024) · Radiology · doi:10.1148/radiol.233051 · Cited by 130
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Phoolchund, A. G. S., & Khakoo, S. I. (2024) · Cancers · doi:10.3390/cancers16020259 · Cited by 137
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection
Fuster, C., Mauro, E., Ferrer, J., Caballol, B., Sanduzzi‐Zamparelli, M., Bruix, J., Fuster, J., Reig, M., Díaz, A., & Forner, A. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.018 · Cited by 138
Self-citationSalem, R., Padia, S. A., Lam, M. G. E. H., Chiesa, C., Haste, P. M., Sangro, B., Toskich, B. B., Fowers, K. D., Herman, J. M., Kappadath, S. C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05956-w · Cited by 120
Self-citationImmune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 138
Fulgenzi, C. A. M., Cheon, J., D’Alessio, A., Nishida, N., Ang, C., Marron, T. U., Wu, L. Y., Saeed, A., Wietharn, B., Cammarota, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.08.024 · Cited by 113
Self-citationLi, B., Li, Y., Zhou, H., Xu, Y., Cao, Y., Cheng, C., Peng, J., Li, H., Zhang, L., Su, K., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000553 · Cited by 110
Bae, S. H., Chun, S.-J., Chung, J.-H., Kim, E., Kang, J.-K., Jang, W. I., Moon, J. E., Roquette, I., Mirabel, X., Kimura, T., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.08.015 · Cited by 117
Xia, T., Zhao, B., Li, B., Lei, Y., Song, Y. S., Wang, Y., Tang, T., & Ju, S. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28982 · Cited by 114
“4 Treating HCC presents a complicated challenge due to its biological heterogeneity, which results in variable risks of recurrence or metastasis as well as different sensitivity to various therapies.”
BackgroundNew concepts in the treatment of hepatocellular carcinoma
Sidali, S., Trépo, E., Sutter, O., & Nault, J. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12286 · Cited by 106
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
Dawson, L. A., Winter, K. A., Knox, J. J., Zhu, A. X., Krishnan, S., Guha, C., Kachnic, L. A., Gillin, M. T., Hong, T. S., Craig, T., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5403 · Cited by 106
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Pinter, M., Pinato, D. J., Ramadori, P., & Heikenwalder, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1258 · Cited by 103
Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives
Ronot, M., Chernyak, V., Burgoyne, A. M., Chang, J., Jiang, H., Bashir, M. R., & Fowler, K. J. (2023) · Radiology · doi:10.1148/radiol.221429 · Cited by 103
Combination locoregional and systemic therapies in hepatocellular carcinoma
Zhong, B., Fan, W., Guan, J. J., Peng, Z., Jia, Z., Jin, H., Jin, Z.-C., Chen, J.-J., Zhu, H., & Teng, G. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00247-4 · Cited by 111
Cisplatin in Liver Cancer Therapy
Hamaya, S., Oura, K., Morishita, A., & Masaki, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310858 · Cited by 103
“2022 update, TACE is recommended for HCC in the intermediate stage with well-defined tumor size, and selective embolization with preserved portal vein blood flow and systemic chemotherapy are recommended for diffuse, invasive, and extensive lesions [140].”
BackgroundLi, Y.-K., Wu, S., Wu, Y., Zhang, W.-H., Wang, Y., Li, Y., Kang, Q., Huang, S.-Q., Zheng, K., Jiang, G.-M., et al. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s462168 · Cited by 100
Tabrizian, P., Holzner, M. L., Ajmera, V. H., Kim, A. K., Zhou, K., Schnickel, G. T., Torosian, K., Hoteit, M. A., Marino, R., Li, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.003 · Cited by 96
Yuan, J., Lv, T., Yang, J., Wu, Z., Yan, L., Yang, J., & Shi, Y. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102546 · Cited by 95
Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review
Martinez, E. C., Landazuri-Navas, S., Vilchez, E., Cantú-Hernández, R. R., Mosquera‐Moscoso, J., Encalada, S., lami, Z. A., Delgado, C. Z., & Cinicola, J. (2023) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4902 · Cited by 106
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Qin, Y., Han, S., Yu, Y., Ding, Q., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.15953 · Cited by 100
Ding, Z., Pan, Y., Shang, T., Jiang, T., Lin, Y., Yang, C., Pang, S., Cui, X., Wang, Y., Feng, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41852-z · Cited by 92
“The primer sequences speci fi c to the promoter region of gene are listed in Supplementary Data 8. and P7 primers.”
Influentialde la Torre‐Aláez, M., Matilla, A. M., Varela, M., Iñarrairaegui, M., Reig, M., Lledó, J. L., Arenas, J. I., Lorente, S., Testillano, M., Márquez, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005457 · Cited by 90
Self-citationTrevisani, F., Vitale, A., Kudo, M., Kulik, L., Park, J., Pinato, D. J., & Cillo, U. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.010 · Cited by 89
Hepatocellular carcinoma: Epidemiology, diagnosis and treatment
Mauro, E., de Castro, T., Zeitlhoefler, M., Sung, M. W., Villanueva, A., Mazzaferro, V., & Llovet, J. M. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101571 · Cited by 104
Self-citationOverview of Complications in Cirrhosis
Premkumar, M., & Anand, A. C. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.04.021 · Cited by 88
Cho, Y., Kim, B. H., & Park, J. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0099 · Cited by 87
Moris, D., Martinino, A., Schiltz, S., Allen, P. J., Barbas, A. S., Sudan, D. L., King, L. Y., Berg, C. L., Kim, C., Bashir, M. R., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70018 · Cited by 96
“65 Exploring the role of ICIs in downstaging is crucial because they have significantly improved the management of intermediate - stage and advanced - stage HCC, potentially making some patients eligible for LT. 115 %).”
Positron emission tomography for the assessment of myocardial viability.
Schelbert, H. R. (1991) · PubMed · Cited by 85
D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00457-1 · Cited by 90
CT/MRI LI-RADS 2024 Update: Treatment Response Assessment
Aslam, A., Chernyak, V., Miller, F. H., Bashir, M. R., Do, R., Sirlin, C. B., Lewandowski, R. J., Kim, C., Kielar, A. Z., Kambadakone, A. R., et al. (2024) · Radiology · doi:10.1148/radiol.232408 · Cited by 83
Chan, S. L., Schüler, M., Kang, Y., Yen, C., Edeline, J., Choo, S. P., Lin, C., Okusaka, T., Weiss, K.-H., Macarulla, T. M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02383-5 · Cited by 82
Self-citationde Baère, T., Roux, C., Deschamps, F., Tselikas, L., & Guiu, B. (2022) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-022-03267-z · Cited by 80
Pοlyzos, S. A., Chrysavgis, L., Vachliotis, I. D., Chartampilas, E., & Cholongitas, Ε. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.010 · Cited by 84
Wu, X., Yang, L., Chen, Y., Chen, Z.-W., Lü, H., Shen, X.-Y., Chi, M., Wang, L., Zhang, H., Chen, J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102367 · Cited by 81
Salié, H., Wischer, L., D’Alessio, A., Godbole, I., Suo, Y., Otto-Mora, P., Beck, J., Neumann, O., Stenzinger, A., Schirmacher, P., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332837 · Cited by 78
Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
Lewis, S. C., Dawson, L. A., Barry, A. S., Stanescu, T., Mohamad, I., & Hosni, A. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100498 · Cited by 80
Tanaka, T., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13797 · Cited by 77
Suddle, A. R., Reeves, H. L., Hubner, R. A., Marshall, A., Rowe, I. A. C., TINIAKOS, D. G., Hübscher, S. G., Callaway, M. P., Sharma, D., See, T. C., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331695 · Cited by 80
“148 149 For the UK population, disease staging according to the BCLC fulfils an important role for prognostication, 150 but the recommended treatment algorithm has been modified (ee section ‘Treatment allocation’).”
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
Lau, G. K. K., Obi, S., Zhou, J., Tateishi, R., Qin, S., Zhao, H., Otsuka, M., Ogasawara, S., George, J., Chow, P. K. H., et al. (2024) · Hepatology International · doi:10.1007/s12072-024-10732-z · Cited by 90
“The definition of surgical resectability or feasibility of local ablation varies in different centers and treatment guidelines (Table 1) [2, 15, 47–51].”
Tran, N. H., Muñoz, S., Thompson, S. M., Hallemeier, C. L., & Bruix, J. (2022) · Hepatology · doi:10.1002/hep.32613 · Cited by 76
Self-citationZhu, X., Huang, C., Shen, Y., Xu, B., Ge, N., Ji, Y., Qu, X.-D., Chen, L., Chen, Y., Li, M., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12530-z · Cited by 75
Minici, R., Siciliano, M. A., Ammendola, M., Santoro, R., Barbieri, V., Ranieri, G., & Laganà, D. (2022) · Cancers · doi:10.3390/cancers15010257 · Cited by 80
“According to the 2022 BCLC strategy [4], HCC should not be treated with TACE only in case of diffuse, infiltrative, and extensive bilobar liver involvement.”
Wang, Q.-B., Li, J., Zhang, Z., Li, Y.-K., Liang, Y.-B., Chen, X.-M., Luo, W.-L., Lakang, Y., Yang, Z.-S., Liu, G., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2489651 · Cited by 74
“According to the Barcelona Clinic Liver Cancer (BCLC) staging system, HCC patients with HVTT, IVCTT, and/or RATT belong to the advanced stage and are recommended with systemic treatments [8].”
Hepatocellular Carcinoma: A Comprehensive Review
Amin, N. A., Anwar, J., Sulaiman, A. A., Naumova, N., & Anwar, N. (2025) · Diseases · doi:10.3390/diseases13070207 · Cited by 82
Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances
Cucarull, B., Tutusaus, A., Rider, P., Hernáez-Alsina, T., Cuño-Gómiz, C., de Frutos, P. G., Colell, A., Marí, M., & Morales, A. (2022) · Cancers · doi:10.3390/cancers14030621 · Cited by 77
Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing
Li, X., Shen, Y., Zhang, L., Guo, X., & Wu, J. H. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188720 · Cited by 73
Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
Zhong, B., Jin, Z., Chen, J.-J., Zhu, H., & Zhu, X. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00293 · Cited by 75
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges
Zheng, S., Chan, S. W., Liu, F., Liu, J., Chow, P. K. H., Toh, H. C., & Hong, W. (2024) · Cancers · doi:10.3390/cancers16081582 · Cited by 80
“Corresponding to BCLC prognosis and treatment strategy, the estimated survival period for each stage is as follows: the early stage is more than 5 years, 2.5 years for the intermediate stage, 2 years for the advanced stage, and only 3 months for the terminal stage [14].”
InfluentialEASL-ERN position paper on liver involvement in patients with Fontan-type circulation
Téllez, L., Payancé, A., Tjwa, E. T. T. L., del Cerro, M. J., Idorn, L., Ovroutski, S., Bruyne, R. D., Verkade, H. J., Rita, F. D., de Lange, C., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.013 · Cited by 71
Finn, R. S., Ryoo, B., Hsu, C., Li, D., Burgoyne, A. M., Cotter, C., Badhrinarayanan, S., Wang, Y., Yin, A., Edubilli, T. R., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00679-x · Cited by 73
Dopazo, C., Søreide, K., Rangelova, E. B., Mieog, S., Carrión-Álvarez, L., Díaz-Nieto, R., Primavesi, F., & Stättner, S. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.107313 · Cited by 70
Artificial intelligence in liver cancer — new tools for research and patient management
Caldéraro, J., Žigutytė, L., Truhn, D., Jaffe, A., & Kather, J. N. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00919-y · Cited by 73
“Since 2017 there have been major breakthroughs in systemic therapeutic options, now with immunotherapy at the forefront of treatment 95 .”
InfluentialMultidisciplinary care for patients with HCC: a systematic review and meta-analysis
Dahan, K. S. E., Reczek, A., Daher, D., Rich, N. E., Yang, J. D., Hsiehchen, D., Zhu, H., Patel, M. S., Molano, M. D. P. B., Sanford, N. N., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000143 · Cited by 69
“[6] In contrast to prior treatment allocation algorithms in which one treatment was recommended for a specific tumor stage, there are now multiple treatment options to consider based on several factors including tumor burden, liver dysfunction, performance status, transplant eligibility, local expertise, and patient p…”
BackgroundResultSelf-citationMandorfer, M., Aigner, E. S., Cejna, M., Ferlitsch, A., Datz, C., Gräter, T., Graziadei, I. W., Gschwantler, M., Hametner‐Schreil, S., Hofer, H., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02229-w · Cited by 69
Odisio, B. C., Albuquerque, J., Lin, Y., Anderson, B., O'Connor, C. S., Rigaud, B., Dimayuga, M. B., Jones, A. K., Fellman, B. M., Huang, S. Y., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00024-x · Cited by 69
Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
Kotsifa, E., Vergadis, C., Vailas, M. G., Machairas, N., Kykalos, S., Damaskos, C., Garmpis, N., Lianos, G. D., & Schizas, D. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030436 · Cited by 68
The future of liver transplantation
Feng, S., Roll, G. R., Rouhani, F. J., & Fueyo, A. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000873 · Cited by 69
Li, M., Bhoori, S., Mehta, N. J., & Mazzaferro, V. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.037 · Cited by 70
Self-citationZhu, X., Li, T., Wang, Q., Yan, K., Ma, S., Lin, Y., Zeng, G., Liu, J., Cao, J., & Wang, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c11257 · Cited by 68
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
Laface, C., Fedele, P., Maselli, F. M., Ambrogio, F., Foti, C., Molinari, P., Ammendola, M., Lioce, M., & Ranieri, G. (2022) · Cancers · doi:10.3390/cancers14164028 · Cited by 66
Romero, A. M., van der Holt, B., Willemssen, F. E. J. A., de Man, R. A., Heijmen, B. J. M., Habraken, S., Westerveld, H. G., van Delden, O. M., Klümpen, H., Tjwa, E. T. T. L., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.03.064 · Cited by 66
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making
Dhanasekaran, R., Suzuki, H., Lemaitre, L., Kubota, N., & Hoshida, Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000513 · Cited by 72
Hobeika, C., Pfister, M., Geller, D. A., Tsung, A., Chan, A. C. Y., Troisi, R. I., Rela, M., Benedetto, F. D., Sucandy, I., Nagakawa, Y., et al. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006365 · Cited by 66
Metadata
- Authors
- Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- University of California, San Francisco (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University of Milan (IT)
- Northwestern University (US)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- The University of Texas Southwestern Medical Center (US)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Bruix, Jordi
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 76
- Issue
- 3
- Pages
- 681-693
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC8866082
- OpenAlex
- W3213277274
- Cited by
- 4,319
- References
- 136
- Citations by year
- 2026: 684 · 2025: 1071 · 2024: 1166 · 2023: 962 · 2022: 424
- FWCI
- 83.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Fundación Científica de la Asociación Española Contra el Cáncer (PI044031)
- National Institutes of Health (R01 R01 MD012565, PI18/00768)
- Horizon 2020 Framework Programme (952103)
- Instituto de Salud Carlos III (AC16/00065, PI18/0358, PI15/00145, PI18/00542, PI19/00742, PI18/00768)
- European Association for the Study of the Liver
- Horizon 2020
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- hepatocellular carcinoma, Barcelona Clinic Liver Cancer staging, outcome prediction, treatment guidelines, evidence-based clinical decision-making
- MeSH terms
- Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Severity of Illness Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
